Ascendis Pharma A/S $ASND is Siren L.L.C.'s 9th Largest Position

Key Points

• Siren L.L.C. has reduced its stake in Ascendis Pharma A/S by 3.3%, now holding 287,366 shares worth approximately $44.8 million.
• Ascendis Pharma reported earnings of ($0.93) per share for the last quarter, surpassing analyst expectations by $0.49.
• Multiple brokerages have recently upgraded their target prices for Ascendis Pharma, with Wells Fargo increasing their target from $289.00 to $295.00.

Siren L.L.C. trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 287,366 shares of the biotechnology company's stock after selling 9,955 shares during the period. Ascendis Pharma A/S accounts for approximately 2.6% of Siren L.L.C.'s holdings, making the stock its 9th largest position. Siren L.L.C. owned about 0.47% of Ascendis Pharma A/S worth $44,789,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ASND. PNC Financial Services Group Inc. raised its holdings in Ascendis Pharma A/S by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company's stock valued at $1,337,000 after acquiring an additional 195 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $28,000. Brooklyn Investment Group grew its position in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 273 shares in the last quarter. GF Fund Management CO. LTD. increased its holdings in shares of Ascendis Pharma A/S by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock worth $241,000 after purchasing an additional 278 shares during the last quarter. Finally, Mariner LLC increased its holdings in shares of Ascendis Pharma A/S by 31.0% in the fourth quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock worth $297,000 after purchasing an additional 511 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ASND shares. Royal Bank Of Canada lifted their target price on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Citigroup reaffirmed a "buy" rating and issued a $290.00 target price (up from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Bank of America lifted their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Oppenheimer reaffirmed an "outperform" rating and issued a $224.00 target price (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Finally, Wedbush lifted their target price on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Buy" and an average price target of $243.36.

Ascendis Pharma A/S Stock Up 0.2%

ASND traded up $0.37 on Friday, hitting $194.27. The company had a trading volume of 357,323 shares, compared to its average volume of 548,125. The company has a market cap of $11.89 billion, a PE ratio of -37.65 and a beta of 0.39. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $199.99. The business's fifty day simple moving average is $180.19 and its 200 day simple moving average is $166.35.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.